CRISPR Used to Treat High Cholesterol in Human Trial

For millions of people struggling with high cholesterol, the standard of care has been the same for decades: taking a daily pill. However, a groundbreaking clinical trial has demonstrated that a single injection using CRISPR gene-editing technology can permanently lower “bad” cholesterol levels. This development marks a potential turning point in cardiovascular medicine, offering a “one-and-done” solution for patients with genetic conditions that make standard treatments ineffective.

The Breakthrough: VERVE-101

The treatment making headlines is called VERVE-101, developed by the biotechnology company Verve Therapeutics. In late 2023, the company released data from its Phase 1b clinical trial, known as the “heart-1” study. This trial represented the first time a base-editing therapy was used in humans to treat a complex disease like high cholesterol.

The results were significant. In patients receiving the highest dose of the therapy, Low-Density Lipoprotein (LDL) cholesterol levels dropped by as much as 55%. For context, this reduction is comparable to or better than what many patients achieve with high-intensity statins or newer injectable drugs like PCSK9 inhibitors, but with a crucial difference: the effects of VERVE-101 are intended to be permanent.

Targeting the PCSK9 Gene

To understand how this treatment works, you have to look at the liver. The liver is responsible for clearing LDL cholesterol from the blood. A gene called PCSK9 produces a protein that interferes with this cleaning process. If you have too much PCSK9 protein, your liver cannot remove cholesterol efficiently, leading to dangerous buildup in the arteries.

VERVE-101 works by turning this gene off.

  • The Delivery: The drug is delivered via lipid nanoparticles (microscopic fat bubbles) that carry the gene-editing instructions directly to the liver.
  • The Edit: Once inside the liver cells, the treatment uses “base editing.” Unlike standard CRISPR, which cuts the DNA double helix, base editing acts like a pencil and eraser. It chemically changes a single letter in the DNA sequence of the PCSK9 gene.
  • The Result: This tiny change creates a “stop” signal, effectively shutting down the production of the PCSK9 protein. With the protein gone, the liver can resume clearing cholesterol from the bloodstream at a high rate.

Who Is This For?

Currently, this treatment is not intended for the average person with slightly elevated cholesterol due to diet. The trial specifically targeted patients with Heterozygous Familial Hypercholesterolemia (HeFH).

HeFH is a genetic condition that causes dangerously high cholesterol levels from birth. People with HeFH are at extreme risk for early heart attacks and stroke, often requiring aggressive medication regimes that include maximum-dose statins (like Lipitor) and regular injections (like Repatha). Despite these treatments, many HeFH patients still cannot reach their target LDL levels. For these individuals, a permanent genetic fix could be lifesaving.

Safety and Risks

While the efficacy data is promising, gene editing carries inherent risks. Because the treatment changes the DNA permanently, any side effects could also be permanent.

In the initial trial, Verve reported some safety concerns:

  1. Liver Enzymes: Some patients experienced transient increases in liver enzymes, suggesting temporary stress on the liver.
  2. Adverse Events: Two serious adverse events were reported in patients with advanced heart disease, including one fatal heart attack. An independent safety board determined the death was due to the patient’s underlying severe heart disease, not the treatment, but regulators and investors remain cautious.
  3. FDA Pause: The FDA had initially placed a hold on the trial in the United States to demand more data, but that hold was lifted in late 2023, allowing Verve to proceed with US-based testing.

challenging the Statin Status Quo

The current model for treating heart disease relies heavily on patient adherence. Statins are effective, but only if people take them. Studies show that nearly 50% of patients stop taking their statins within a year of being prescribed them. This leads to “rebound” cholesterol levels and continued heart risks.

A gene-editing therapy changes the paradigm from “chronic care” to “cure.” By removing the need for daily compliance, healthcare providers can ensure the patient is protected for years, potentially decades, after a single visit. This shift could drastically reduce the global burden of cardiovascular disease, which remains the leading cause of death worldwide.

What Happens Next?

This technology is still years away from your local pharmacy. Verve Therapeutics is continuing to monitor the safety of the initial participants and is planning larger Phase 2 trials to establish the ideal dosage and safety profile.

Additionally, the cost will be a major factor. Gene therapies currently on the market, such as those for sickle cell disease, cost millions of dollars per patient. While a cholesterol treatment would likely need to be cheaper to be viable for a larger population, it will almost certainly be a high-cost premium therapy initially reserved for the highest-risk genetic cases.

Frequently Asked Questions

Is this treatment available now? No. VERVE-101 is currently in clinical trials. It is only available to a small number of participants in specific study locations. It will likely take several years of testing and FDA approval before it is available to the public.

Does this use the same CRISPR that cuts DNA? It uses a modified version called “base editing.” Traditional CRISPR acts like scissors, cutting the DNA strands. Base editing is more precise and acts like a pencil, chemically changing one DNA letter to another without making a double-strand break. This is generally considered safer for this type of application.

Can this replace diet and exercise? For the general population, lifestyle changes remain the first line of defense. This therapy is currently being tested only for people with genetic conditions (HeFH) where diet and exercise are biologically incapable of lowering cholesterol enough to prevent heart attacks.

Are the effects truly permanent? The change to the DNA is permanent in the edited liver cells. Since the liver regenerates, the edit is passed down to new liver cells. Animal studies suggest the effect could last a lifetime, and early human data supports this longevity, but long-term human studies are needed to confirm it.